Accueil > Actualité
Actualite financiere : Actualite bourse

Sanofi: US FDA approves Dupixent

( - The US FDA has approved Dupixent (dupilumab) for the treatment of nodular prurigo in adults.

Dupixent becomes the first and only drug that is specifically indicated for the treatment of nodular prurigo in the US.

Nodular prurigo is a chronic, disabling dermatological disease with a type 2 inflammatory signature.

The FDA has granted priority review to Dupixent's application for the treatment of nodular prurigo - a status that is granted to drugs that have the potential to significantly improve the diagnosis, treatment or prevention of serious diseases.

Sanofi said, Dupixent has the potential to transform the gold standard treatment of nodular prurigo, alleviate its main symptoms, such as itching, and promote skin healing.

Copyright (c) 2022 All rights reserved.




Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.
Indices et cours différés d’au moins 15 mn | Cotations boursières fournies par ABC Bourse.